Eriliset

Eriliset is a brand name for the drug teriflunomide, which is used in the treatment of relapsing forms of multiple sclerosis (MS). Multiple sclerosis is a chronic disease affecting the central nervous system, characterized by the immune system attacking the myelin sheath that protects nerve fibers. This attack can lead to a range of symptoms including fatigue, numbness, vision problems, and difficulty with coordination.

Teriflunomide works by inhibiting an enzyme called dihydroorotate dehydrogenase (DHODH). This enzyme is important for the proliferation of lymphocytes, a type of white blood cell that plays a key role in the immune response. By reducing the activity of lymphocytes, teriflunomide helps to decrease the inflammatory processes that contribute to MS relapses and disability progression.

Eriliset is taken orally as a tablet, usually once a day. It is considered an immunomodulatory drug, meaning it modifies the immune system's activity. Clinical trials have shown that Erliset can reduce the frequency of relapses and slow the accumulation of disability in individuals with relapsing MS. It is important for patients to discuss the potential benefits and risks of Erliset with their healthcare provider, as with any medication. Side effects can include hair thinning, diarrhea, nausea, and liver enzyme elevations. Regular monitoring of liver function may be recommended during treatment.